A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Tirzepatide identity.
ClinicalTrials.gov posted a newer version of NCT07463846, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2]
ClinicalTrials.gov posted a newer version of NCT07734792, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2]
We added a plain-language reader guide with cited answers, re-checked the Zepbound label and Drugs@FDA records, and added FDA’s August 2026 approval of a cardiovascular indication for Mounjaro, the SURPASS-CVOT label updates for Mounjaro and Zepbound, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026).
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Mounjaro and Zepbound
Profile summary
Before
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
After
A GIP and GLP-1 receptor agonist approved by FDA as Mounjaro and Zepbound. In August 2026 FDA added a cardiovascular risk-reduction indication for Mounjaro.
Evidence note
Before
The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]
After
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]; U.S. Food and Drug Administration [sources: fda-mounjaro-s044-s045-approval-2026, fda-unapproved-glp1-concerns-2026-r2]
We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
Showing the latest 100 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.
PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05536804 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06191848 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06603571 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06700538 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06774079 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06854614 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06857942 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06861439 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06911203 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06937086 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06937099 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07078838 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07099742 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07504172 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07527910 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07697391 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07782359 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07803744 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07811895 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07812636 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07817875 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07825857 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07829198 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07842640 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07846865 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07847515 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07866183 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07868354 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07874828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07881432 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07881458 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07889453 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07889648 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07893457 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07906041 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 42735799 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Journal Article, with publication-date metadata of 2026-09-14 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42810204 in Medicina clinica as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42831032 in Obesity pillars as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42922752 in bioRxiv : the preprint server for biology as Journal Article, Preprint, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42969740 in Molecular pharmaceutics as Journal Article, with publication-date metadata of 2026-11-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 43009382 in Obesity research & clinical practice as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 43030521 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-10-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 43030785 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-06 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
PubMed lists PMID 42695200 in Oral diseases as Letter, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 15 for the reviewed Tirzepatide label family with a published date of 2025-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 16 for the reviewed Tirzepatide label family with a published date of 2025-02-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 17 for the reviewed Tirzepatide label family with a published date of 2025-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 18 for the reviewed Tirzepatide label family with a published date of 2025-03-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 19 for the reviewed Tirzepatide label family with a published date of 2025-04-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 21 for the reviewed Tirzepatide label family with a published date of 2025-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 22 for the reviewed Tirzepatide label family with a published date of 2025-05-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 23 for the reviewed Tirzepatide label family with a published date of 2025-07-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 28 for the reviewed Tirzepatide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 30 for the reviewed Tirzepatide label family with a published date of 2025-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Tirzepatide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.
The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
The Federal Register published notice 2024-04157, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.
The Federal Register published notice 2025-20548, attributed to FDA and its parent HHS department, on 2025-11-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.
The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.
The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
PubMed lists PMID 41258966 in Hepatology international as Letter, Comment, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
The official Drugs@FDA dataset lists original submission 1 for NDA 215866 with status AP dated 2022-05-13, and names tirzepatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients.
PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide.